(Q35000943)

5 August 2017

1 reference

title

Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? (English)

1 reference

5 August 2017

Sheila A Doggrell

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

Expert Opinion on Pharmacotherapy

5 August 2017

published in

1 reference

5 August 2017

volume

3

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1543-1556

1 reference

Therapeutic potential of angiotensin II receptor antagonists

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Treatment with irbesartan or atenolol improves endothelial function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Short-term effects of angiotensin II receptor blockade in patients with primary glomerulonephritis: pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.11.1543

10.1517/14656566.3.11.1543

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference